First Time Loading...

Shandong Bailong Chuangyuan Bio-Tech Co Ltd
SSE:605016

Watchlist Manager
Shandong Bailong Chuangyuan Bio-Tech Co Ltd Logo
Shandong Bailong Chuangyuan Bio-Tech Co Ltd
SSE:605016
Watchlist
Price: 27.93 CNY 0.54% Market Closed
Updated: May 5, 2024
Section:
 

Wall Street
Price Targets

Price Targets Summary
Shandong Bailong Chuangyuan Bio-Tech Co Ltd

Wall Street analysts forecast Shandong Bailong Chuangyuan Bio-Tech Co Ltd stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Shandong Bailong Chuangyuan Bio-Tech Co Ltd is 27.23 CNY with a low forecast of 20.6 CNY and a high forecast of 34.65 CNY.

Lowest Forecast
Wall Street Target
20.6 CNY
26% Downside
Average Forecast
Wall Street Target
27.23 CNY
2% Downside
Highest Forecast
Wall Street Target
34.65 CNY
24% Upside
Lowest
Price Target
20.6 CNY
26% Downside
Average
Price Target
27.23 CNY
2% Downside
Highest
Price Target
34.65 CNY
24% Upside
Shandong Bailong Chuangyuan Bio-Tech Co Ltd Competitors:
Price Targets
ORON
Orior AG
3% Downside
K
KING
Kingfish Company NV
46% Upside
Z
300908
Zhongjing Food Co Ltd
41% Upside
A
ABLEGLOB
Able Global Bhd
4% Upside
ORON
Orior AG
3% Downside
K
KING
Kingfish Company NV
46% Upside
Z
300908
Zhongjing Food Co Ltd
41% Upside
A
ABLEGLOB
Able Global Bhd
4% Upside
2050
Savola Group Company SJSC
1% Downside
002991
Gan Yuan Foods Co Ltd
25% Upside
MDLZ
Mondelez International Inc
21% Upside
603711
Xiangpiaopiao Food Co Ltd
20% Upside

Revenue
Forecast

Revenue Estimate
Shandong Bailong Chuangyuan Bio-Tech Co Ltd

For the last 3 years the compound annual growth rate for Shandong Bailong Chuangyuan Bio-Tech Co Ltd's revenue is 20%. The projected CAGR for the next 4 years is 26%.

20%
Past Growth
26%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Shandong Bailong Chuangyuan Bio-Tech Co Ltd

For the last 3 years the compound annual growth rate for Shandong Bailong Chuangyuan Bio-Tech Co Ltd's operating income is 16%. The projected CAGR for the next 4 years is 38%.

16%
Past Growth
38%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Shandong Bailong Chuangyuan Bio-Tech Co Ltd

For the last 3 years the compound annual growth rate for Shandong Bailong Chuangyuan Bio-Tech Co Ltd's net income is 22%. The projected CAGR for the next 3 years is 41%.

22%
Past Growth
41%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Shandong Bailong Chuangyuan Bio-Tech Co Ltd's stock price target?
Price Target
27.23 CNY

According to Wall Street analysts, the average 1-year price target for Shandong Bailong Chuangyuan Bio-Tech Co Ltd is 27.23 CNY with a low forecast of 20.6 CNY and a high forecast of 34.65 CNY.

What is Shandong Bailong Chuangyuan Bio-Tech Co Ltd's Revenue forecast?
Projected CAGR
26%

For the last 3 years the compound annual growth rate for Shandong Bailong Chuangyuan Bio-Tech Co Ltd's revenue is 20%. The projected CAGR for the next 4 years is 26%.

What is Shandong Bailong Chuangyuan Bio-Tech Co Ltd's Operating Income forecast?
Projected CAGR
38%

For the last 3 years the compound annual growth rate for Shandong Bailong Chuangyuan Bio-Tech Co Ltd's operating income is 16%. The projected CAGR for the next 4 years is 38%.

What is Shandong Bailong Chuangyuan Bio-Tech Co Ltd's Net Income forecast?
Projected CAGR
41%

For the last 3 years the compound annual growth rate for Shandong Bailong Chuangyuan Bio-Tech Co Ltd's net income is 22%. The projected CAGR for the next 3 years is 41%.

ALPHA SPREAD
Join more than 134,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.